Core Viewpoint - The approval of innovative traditional Chinese medicine (TCM) products, such as the pediatric fever-reducing patch, reflects the accelerated modernization and industrialization of TCM, driven by policy guidance, scientific breakthroughs, and clinical demand [1][2]. Group 1: Recent Developments in TCM - Since 2021, 52 new TCM products have been approved, with a notable increase in the number of innovative drugs, indicating a rapid pace of TCM new drug approvals [1][3]. - The approval of TCM new drugs is supported by the "14th Five-Year Plan for TCM Development," which emphasizes the development of new drugs based on ancient classic formulas and effective components [1][3]. Group 2: Research and Development Trends - A significant characteristic of recent TCM drug approvals is the focus on ancient classic formulas, with 23 out of the 52 new drugs being based on these traditional formulations [3]. - The integration of big data, artificial intelligence, and genomics into TCM research has enhanced precision and efficiency, while collaboration among experts from various fields has provided comprehensive solutions for TCM development [3]. Group 3: Market Demand and Future Outlook - Growing public interest in health and traditional culture has led to increased market demand for TCM, prompting higher investment and research enthusiasm from companies in this sector [2]. - The acceleration of TCM new drug approvals is reshaping treatment models and providing multiple benefits to patients, particularly in challenging diseases like cancer [4]. - The government aims to enhance TCM quality and promote high-quality development in the industry by focusing on significant chronic diseases and optimizing the approval process for innovative TCM drugs [4].